Plantone Domenico, De Angelis Floriana, Doshi Anisha, Chataway Jeremy
Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, University College London, London, WC1N 3BG, UK.
CNS Drugs. 2016 Jun;30(6):517-26. doi: 10.1007/s40263-016-0340-9.
Secondary progressive multiple sclerosis (SPMS) is diagnosed retrospectively and involves a clinical course characterized by a progressive accumulation of neurological disability, independent of relapses, following an initial relapsing-remitting (RR) phase. Our incomplete understanding of the pathological mechanisms underlying neurodegeneration in multiple sclerosis (MS) may explain why, to date, there is no definitive imaging or laboratory test that is able to inform us when the disease is clearly entering into a progressive phase and why the vast majority of clinical trials testing immunosuppressant and immunomodulating drugs in SPMS patients has so far yielded disappointing or mixed results. Here we discuss the definition(s) of SPMS and how it may vary, outcome measurements (current and emerging) and modern trial design.
继发进展型多发性硬化(SPMS)通过回顾性诊断,其临床病程特征为在最初的复发缓解期(RR)之后,出现与复发无关的神经功能障碍进行性累积。我们对多发性硬化(MS)神经退行性变潜在病理机制的理解尚不完整,这或许可以解释为何至今尚无明确的影像学或实验室检查能够告知我们疾病何时明显进入进展期,以及为何绝大多数针对SPMS患者的免疫抑制剂和免疫调节药物的临床试验迄今结果令人失望或好坏参半。在此,我们将讨论SPMS的定义及其可能的差异、结局测量指标(现有和新出现的)以及现代试验设计。